BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $595,408 | -30.2% | 8,747 | -16.3% | 0.02% | -30.8% |
| Q2 2023 | $853,115 | +27.1% | 10,451 | +15.5% | 0.03% | +13.0% |
| Q1 2023 | $671,271 | -38.8% | 9,048 | -31.6% | 0.02% | -48.9% |
| Q4 2022 | $1,096,337 | -4.3% | 13,228 | +228.1% | 0.04% | -13.5% |
| Q3 2022 | $1,145,000 | +28.7% | 4,032 | +57.0% | 0.05% | +26.8% |
| Q2 2022 | $890,000 | +4.3% | 2,568 | +30.4% | 0.04% | 0.0% |
| Q1 2022 | $853,000 | -3.6% | 1,969 | +15.1% | 0.04% | -21.2% |
| Q4 2021 | $885,000 | +15.4% | 1,711 | +8.1% | 0.05% | -24.6% |
| Q3 2021 | $767,000 | +31.1% | 1,583 | +21.9% | 0.07% | +13.1% |
| Q2 2021 | $585,000 | +4.3% | 1,299 | -11.6% | 0.06% | -28.2% |
| Q1 2021 | $561,000 | +50.0% | 1,469 | +24.8% | 0.08% | +4.9% |
| Q4 2020 | $374,000 | +37.0% | 1,177 | +6.6% | 0.08% | +5.2% |
| Q3 2020 | $273,000 | -3.5% | 1,104 | +3.2% | 0.08% | -39.8% |
| Q2 2020 | $283,000 | – | 1,070 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |